3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
2727
Lung Neoplasms
944
Small Cell Lung Carcinoma
447
Neoplasms
419
Colorectal Neoplasms
407
Breast Neoplasms
355
Melanoma
332
Ovarian Neoplasms
316
Neoplasm Metastasis
280
Pancreatic Neoplasms
251
Squamous Cell Carcinoma of Head and Neck
232
Stomach Neoplasms
227
Carcinoma, Renal Cell
214
Triple Negative Breast Neoplasms
189
Head and Neck Neoplasms
178
Prostatic Neoplasms
152
Esophageal Neoplasms
149
Endometrial Neoplasms
145
Uterine Cervical Neoplasms
139
Urinary Bladder Neoplasms
132
Mesothelioma
115
Carcinoma
106
Carcinoma, Hepatocellular
104
Colonic Neoplasms
103
Carcinoma, Transitional Cell
99
Sarcoma
98
Kidney Neoplasms
74
Mesothelioma, Malignant
72
Cholangiocarcinoma
67
Liver Neoplasms
66
Interventions
osimertinib
1
Gefitinib
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
×
Thoracic
×
Clear all
NCT02296125
2026-04-21
FLAURA
AstraZeneca
Phase 3
Completed
674 enrolled
21 charts
1 FDA